Titre : | Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002 (2006) |
Titre traduit : | (Prévalence des infections à l'hépatite et au VIH et taux de vaccination chez ls patients débutant un traitement à l'héroïne sous surveillance entre 1994 et 2002) |
Auteurs : | GERLICH M. ; GSCHWEND P. ; A. UCHTENHAGEN ; A. KRAMER ; J. REHM |
Type de document : | Article : Périodique |
Dans : | European Journal of Epidemiology (Vol.21, n°7, July 2006) |
Article en page(s) : | 545-549 |
Langues: | Anglais |
Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
Mots-clés : |
Thésaurus mots-clés HEPATITE ; VIH ; TRAITEMENT DE MAINTENANCE ; DISTRIBUTION CONTROLEE ; HEROINE ; ENQUETE ; PREVALENCEThésaurus géographique SUISSE |
Résumé : | Background: Hepatitis C virus (HCV) remains very prevalent in injection drug users (IDUs). In spite of recommended vaccinations against hepatitis A virus (HAV) and hepatitis B virus (HBV), many IDUs remain susceptible to HAV and HBV. Study population and methods: ?Patients entering heroin-assisted treatment between 2000 and 2002 (N = 210) were compared for infectious disease status with patients entering this treatment in 1998 (N = 243) and between 1994 and 1996 (N = 1035). Infection status was determined with the aid of questionnaires and blood tests for antibodies against HAV, HBV core antigen, HCV and HIV. Results: ?In the cohort 20002002 78.3% of the patients were HCV positive, 53.3% were HBV positive, 41.2% were HAV positive and 12.6% were HIV positive. In comparison to the cohorts entering the heroin- assisted treatment at an earlier time, there was a significant reduction of HBV and HAV infections, but not of HCV and HIV infections. 15.6% of the patients entering between 2000 and 2002 were vaccinated against HBV and 10.3% against HAV. 31.1% of patients at entrance were susceptible for HBV and 48.5% for HAV. In comparison to patients entering treatment in 1998 there was no significant increase in patients who were vaccinated against HBV. Conclusions:This data illustrates the need for improving HCV prevention and more consequent vaccination against HBV and HAV in IDUs. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 34 |
Affiliation : | Research Institute for Public Health and Addiction, Zürich, Switzerland |
Numéro Toxibase : | 1301803 |
Centre Emetteur : | 13 OFDT |
Accueil